FDA approves NVS’ Pluvicto*, a radioligand for CRPC: https://www.globenewswire.com/news-release/2022/03/23/2408996/0/en/Novartis-PluvictoTM-approved-by-FDA-as-first-targeted-radioligand-therapy-for-treatment-of-progressive-PSMA-positive-metastatic-castration-resistant-prostate-cancer.html NVS obtained this agent from the ECYT buyout in 2018 (#msg-144295734). *f/k/a 177Lu-PSMA-617.